Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 6/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.47 |
| ▸ | POLA1 | P09884 | 1/20 | 0.46 |
| ▸ | PNP | P00491 | 1/20 | 0.43 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.43 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.39 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7809886 | 0.88 | XDH (0.57) | XDHHTTNCOA1SMN1; SMN2NCOA3 | |
| SCHEMBL27762591 | 0.85 | XDH (0.50) | XDHHTTNCOA1SMN1; SMN2NCOA3 | |
| SCHEMBL9059986 | 0.83 | XDH (0.55) | XDHHTTNCOA1SMN1; SMN2NCOA3 | |
| SCHEMBL716338 | 0.79 | XDH (0.42) | XDHHTTNCOA1SMN1; SMN2NCOA3 | |
| SCHEMBL7862551 | 0.79 | PNP (0.44) | XDHPNPGDAGRIA1GRIA2 | |
| SCHEMBL28237493 | 0.77 | PNP (0.46) | XDHPOLA1PNPGDAPDE5A | |
| SCHEMBL7680703 | 0.74 | XDH (0.60) | XDHPOLA1PNPGDAPDE5A | |
| SCHEMBL29450710 | 0.74 | XDH (0.44) | XDHPOLA1PNPGDAPDE5A | |
| SCHEMBL595204 | 0.73 | PNP (0.57) | XDHPNPGDAGRIA1GRIA2 | |
| SCHEMBL3222570 | 0.73 | USP2 (0.44) | XDHHTTPOLA1GDAPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210147502-A1 | RECOMBINANT CANCER THERAPEUTIC CYTOKINE | UNIV VIRGINIA COMMONWEALTH (US) | 2021-05-20 | — | — | US | disclosed |
| US-20200384135-A1 | CANCER IMAGING WITH THERAPY: THERANOSTICS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2020-12-10 | — | — | US | disclosed |
| EP-3004153-B1 | RECOMBINANT CANCER THERAPEUTIC CYTOKINE | UNIV VIRGINIA COMMONWEALTH (US) | 2019-10-30 | — | — | EP | disclosed |
| US-10166300-B2 | Tripartite cancer theranostic nucleic acid constructs | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2019-01-01 | — | — | US | disclosed |
| US-20180305429-A1 | RECOMBINANT CANCER THERAPEUTIC CYTOKINE | UNIV VIRGINIA COMMONWEALTH (US) | 2018-10-25 | — | — | US | disclosed |
| US-9951114-B2 | Recombinant cancer therapeutic cytokine | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2018-04-24 | — | — | US | disclosed |
| EP-3003022-B1 | USE OF A TRUNCATED CCN1 PROMOTER FOR CANCER DIAGNOSTICS, THERAPEUTICS AND THERANOSTICS | UNIV VIRGINIA COMMONWEALTH (US) | 2017-11-22 | — | — | EP | disclosed |
| EP-3004872-B1 | MDA-9/SYNTENIN PROMOTER TO IMAGE AND TREAT METASTATIC CANCER CELLS | UNIV VIRGINIA COMMONWEALTH (US) | 2017-10-18 | — | — | EP | disclosed |
| US-9750823-B2 | Use of a truncated CCN1 promoter for cancer diagnostics, therapeutics and theranostics | UNIV VIRGINIA COMMONWEALTH (US) | 2017-09-05 | — | — | US | disclosed |
| US-9701985-B2 | mda-9/syntenin promoter to image and treat metastatic cancer cells | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2017-07-11 | — | — | US | disclosed |
| EP-3003022-A1 | USE OF A TRUNCATED CCN1 PROMOTER FOR CANCER DIAGNOSTICS, THERAPEUTICS AND THERANOSTICS | Virginia Commonwealth University (US) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014209553-A1 | USE OF A TRUNCATED CCN1 PROMOTER FOR CANCER DIAGNOSTICS, THERAPEUTICS AND THERANOSTICS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014197598-A2 | TRIPARTITE CANCER THERANOSTIC NUCLEIC ACID CONSTRUCTS | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-12-11 | — | — | WO | disclosed |
| WO-2014197535-A1 | RECOMBINANT CANCER THERAPEUTIC CYTOKINE | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2014-12-11 | — | — | WO | disclosed |
| US-20140227182-A1 | CANCER IMAGING WITH THERAPY: THERANOSTICS | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-08-14 | — | — | US | disclosed |
| US-20130263296-A1 | CANCER IMAGING WITH THERAPY: THERANOSTICS | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-10-03 | — | — | US | disclosed |
| EP-2633063-A2 | CANCER IMAGING WITH THERAPY: THERANOSTICS | Virginia Commonwealth University (US) | 2013-09-04 | — | — | EP | disclosed |
| WO-2012058522-A2 | CANCER IMAGING WITH THERAPY: THERANOSTICS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2012-05-03 | — | — | WO | disclosed |
| EP-1372664-A1 | USE OF CERTAIN STEROIDS FOR TREATMENT OF BLOOD CELL DEFICIENCIES | Hollis-Eden Pharmaceuticals Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002069977-A1 | USE OF CERTAIN STEROIDS FOR TREATMENT OF BLOOD CELL DEFICIENCIES | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2002-09-12 | — | — | WO | disclosed |